Latest News about SNY
Recent news which mentions SNY
Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?
January 29, 2022
From Motley Fool
From Benzinga
From Benzinga
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
January 21, 2022
From Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
From Benzinga
3 Under-the-Radar COVID Stocks
January 19, 2022
From Motley Fool
From MarketWatch
3 Top Biotech Stocks to Buy Right Now
January 15, 2022
From Motley Fool
From Benzinga
These 2 Nasdaq Stocks Could Carry Your Portfolio for Years
January 11, 2022
From Motley Fool
Acasti Pharma: Bouncing Back With a New Drug Pipeline
January 04, 2022
From Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
From Benzinga
3 Ultra-Cheap Stocks to Buy Right Now
December 28, 2021
From Motley Fool
From Benzinga
Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront
December 21, 2021
Tickers
SNY
From Benzinga
Drug makers move forward with new COVID-19 booster candidates amid omicron’s spread and mass booster campaigns
December 15, 2021
From MarketWatch
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
December 15, 2021
From Benzinga
Omicron variant remains a ‘very high’ risk as it spreads fast and shows resistance to vaccines, but WHO says more data needed to know if it’s more lethal
December 15, 2021
From MarketWatch
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
December 15, 2021
From Benzinga
From MarketWatch
3 Stocks That Can Make You Rich in Just a Few Years
December 14, 2021
From InvestorPlace
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
December 14, 2021
Tickers
SNY
From Benzinga
Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack
December 14, 2021
From Benzinga
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
December 13, 2021
From Benzinga
From Benzinga
3 Beaten-Down Dividend Stocks -- Are They Bargins Now?
December 06, 2021
From Motley Fool
Regeneron: Surfing on Covid, With More Under the Surface
December 02, 2021
From InvestorPlace
Is High Pressure Good for Drug Development?
December 02, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.